Rybelsus (semaglutide) is an FDA-approved medication used to lower blood sugar in adults with Type 2 diabetes
Make An Appointment Your health is our prioritythe best care from our best orthopaedic surgeons
MASH, formerly known as non-alcohol related steatohepatitis (NASH), is characterized by inflammation and damage of the liver caused by the accumulation of fat cells (steatosis) without significant alcohol consumption, which can lead to liver fibrosis (scarring), cirrhosis (severe scarring of the liver) and liver failure
Several key factors contributed to its popularity: Cost Savings: Brand-name semaglutide medications can be expensive, especially for patients without insurance coverage or with high out-of-pocket costs
Important Dates to Know Program starts: July 1, 2026 Program ends: December 31, 2027 (18 months total) Applications accepted: Starting July 1, 2026 Is this permanent